Wednesday, September 27, 2023
Healiva®, a company dedicated to enhancing the quality of life for patients through precision medicine for chronic wound treatment, has announced a strategic partnership with the Center Hospitalier Universitaire Vaudois (CHUV) for the production and approval of their autologous epidermal equivalent, EpiDex®. EpiDex®, sourced from the patient's hair, offers a non-invasive solution for treating severe venous leg ulcers.
Dr. Priyanka Dutta-Passecker, co-founder and CEO of Healiva, expressed excitement about the collaboration, stating, "We are pleased to partner with CHUV for EpiDex® production. This partnership with a center renowned for skin cell therapy excellence is a pivotal step in our plan to bring EpiDex® to market."
This collaboration provides Healiva access to CHUV's production facilities meeting Good Manufacturing Practice (GMP) standards (CHUV-CPC), their specialized expertise in Advanced Therapy Medicines (ATMPs), and the opportunity for both partners to combine their complementary skills in cell therapy for chronic and acute wound treatment.
EpiDex® is produced by cultivating cells from the patient's hair to create autologous epidermal discs. These discs are then applied to the wound at the treatment center, stimulating the wound healing process. Manufacturing EpiDex® at CHUV-CPC will enable Healiva to offer this innovative treatment to patients in Switzerland.
Dr. Jean-François Brunet (PhD), director of CHUV-CPC, expressed optimism about Healiva's technology, stating, "Healiva’s technology has the potential to revolutionize the treatment of people with chronic wounds. We are fully committed to leveraging our expertise in these technologies to support EpiDex® production.